MailBuild Complex Newsletter Template

BIOTECHNICA, Europe's leading annual biotech and life sciences event, will run from 5 to 7 October in Hannover, Germany, with an emphasis on business development and knowledge transfer. Established in 1985, BIOTECHNICA is comprised of a trade fair, a partnering service, a conference, an award competition, and a career program.

Stephan Ph. Kühne, Member of the Board at BIOTECHNICA organizer Deutsche Messe AG, explains that, “BIOTECHNICA is where the industry turns for inspiration. Sellers meet buyers, investors evaluate trends and innovations, peers network with each other, and the latest scientific findings reach a broad professional audience.”

According to Kühne, the trade fair features small, highly specialized firms exhibiting alongside such industry-leading names as Corning Life Sciences, Eppendorf, Merck, Qiagen, Sartorius, and Thermo Fisher Scientific. Concurrently, the partnering function helps potential business partners identify and connect with each other while the conference – with more than 500 speakers from science, industry and politics – promotes education and knowledge-sharing.

Editor's corner

High summer normally means quieter times in the partnering arena, but with three significant deals already this month, 2010 appears to be an exception to the rule.

We are getting ready for a hectic spell of travel over the coming months - BioPharm America, Pharma CI Conference, BioBusiness Network, BIOTECHNICA, BioPartnering Europe, BIO-Europe and euroPLX 44... Will you be there? Why not request a meeting with us or visit our exhibition stand?

Share your views and opinions with us, you can email me and I will incorporate valuable perspectives into our news updates going forward.

In the news

New and updated reports

Provides comprehensive understanding and unprecedented access to the pre-clinical stage partnering agreements entered into by the worlds leading biopharma companies Buy now

UPDATED: Option & Evaluation Agreements in Pharma and Biotech

Providing detailed understanding and analysis of how and why companies enter option and evaluation deals, plus access to actual option and evaluation agreements Buy now

NEW: Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition

provides detailed understanding and analysis of how and why companies enter royalty financing deals Buy now

NEW: Clinical Stage Partnering Terms and Agreements in Pharma and Biotech, 2nd edition

Provides comprehensive understanding and unprecedented access to the clinical stage partnering agreements entered into by the worlds leading biopharma companies. Buy now

UPDATED: Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 3rd edition

Providing detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals, plus access to actual agreements. Buy now

UPDATED: Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 3rd edition

Providing detailed understanding and analysis of how and why companies enter M&A deals, plus access to actual M&A agreements. Buy now

NEW: Partnering Agreements with Bigpharma

Partnering Agreements with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. Buy now

Partnering round-up

Articles of the month

Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice, processes, latest trends and regulations:

Metabolism deals were one of the dominant headline makers based on a headline value in Q2 2010. There were a total of 23 deals announced in Q2 related to diabetes. More

Aspen Pharmacare is set to acquire the drug making arm of Australia's Sigma Pharmaceuticals for $804 million. This would provide Aspen with approximately a quarter of Australia's generic drug market. More

Investor power has resulted in Charles River abandoning its proposed acquisition of Wuxi Pharma. Despite promises of considerable cost savings as a result of the deal, investors remained unconvinced the deal was in the comapny’s best interests. As a result of the termination, Charles River is obliged to pay Wuxi Pharma a $30 million break-up fee. More

Shire’s mission to become the largest specialty pharma company took another step towards reality with the acquisition of gastrointestinal specialty company Movetis, in a deal valued at $565 million. More

Seattle Genetics and Genentech have expanded their existing antibody-drug conjugate collaboration, in order to deliver additional preclinical ADC compounds. More

Scorecard update

Forthcoming Events

People on the move

Jill Carroll, Evelyn Graham, Chip Clark, Gregory Miller, Robert Stewart, Benoit Martin........

If you have news about a business development executive who is on the move - let us know!

Partnering resources

Current Partnering maintains and regularly updates this list of useful resources for dealmakers across all industries. The following topic areas are available - updated regularly:

About Current Partnering

Current Partnering is an online provider of best practice, business information and intelligence for deal makers. We search out the latest information so you don’t have to and place it in one location, saving you precious time and resources.

Advertising and sponsorship

Current Partnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.

Mail: Wildwood Ventures Ltd., Eco Business Centre, Amy Johnson Way, Clifton Moor, York, YO30 4AG, United Kingdom

Dealmakers News: August 2010